Mineralys Therapeutics, Inc.(NASDAQ:MLYS) 
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in...
Website: https://mineralystx.com
Founded: 2019
IPO Price: $16 (Feb 10, 2023)
CEO: Jon Congleton
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 13.28
H 13.49
L 12.05
C 12.40
V 1,581,180
10EMA 12.40
20EMA 12.40
60EMA 12.40
120EMA 12.40
250EMA 12.40